1. Product Overview
2. Research Methodology
3. Executive Summary
4. Impact of COVID-19
on Global In Silico Drug Discovery Market
5. Voice of Customer
6.
Global In Silico Drug Discovery Market Outlook
6.1. Market Size &
Forecast
6.1.1. By Value
6.2. Market Share &
Forecast
6.2.1. By Component (Software, Software-as-a-Service,
Consultancy-as-a-Service)
6.2.2. By Workflow (Discovery, Pre-Clinical Tests, Clinical
Trials)
6.2.2.1.
By Discovery (Target
Identification, Target Validation, Lead Discovery)
6.2.3. By Software Type (Molecular Modeling & De Novo Drug
Design Software, Pharmacophore Modeling Software)
6.2.4. By Technology (Artificial Intelligence, Graphics
Processing Unit, Others)
6.2.5. By Therapeutic Area (Human Immunodeficiency Virus (HIV),
Infectious Diseases, Metabolic Disorders, Oncology Disorders, Others)
6.2.6. By End User (Biotechnology & Pharmaceutical
Companies, Contract Research Organizations, Academic & Research
Organizations, Others)
6.2.7. By Company (2021)
6.2.8. By Region
6.3. Market Map
7.
North America In Silico Drug Discovery Market Outlook
7.1. Market Size &
Forecast
7.1.1. By Value
7.2. Market Share &
Forecast
7.2.1. By Component (Software, Software-as-a-Service,
Consultancy-as-a-Service)
7.2.2. By Workflow (Discovery, Pre-Clinical Tests, Clinical
Trials)
7.2.2.1.
By Discovery (Target
Identification, Target Validation, Lead Discovery)
7.2.3. By Software Type (Molecular Modeling & De Novo Drug
Design Software, Pharmacophore Modeling Software)
7.2.4. By Technology (Artificial Intelligence, Graphics
Processing Unit, Others)
7.2.5. By Therapeutic Area (Human Immunodeficiency Virus (HIV),
Infectious Diseases, Metabolic Disorders, Oncology Disorders, Others)
7.2.6. By End User (Biotechnology & Pharmaceutical
Companies, Contract Research Organizations, Academic & Research
Organizations, Others)
7.2.7. By Country
7.3. North America:
Country Analysis
7.3.1. United States In
Silico Drug Discovery Market Outlook
7.3.1.1.
Market Size & Forecast
7.3.1.1.1.
By Value
7.3.1.2.
Market Share & Forecast
7.3.1.2.1.
By Component
7.3.1.2.2.
By Workflow
7.3.1.2.3.
By Software Type
7.3.1.2.4.
By Technology
7.3.1.2.5.
By Therapeutic Area
7.3.1.2.6.
By End User
7.3.2. Canada In Silico
Drug Discovery Market Outlook
7.3.2.1.
Market Size & Forecast
7.3.2.1.1.
By Value
7.3.2.2.
Market Share & Forecast
7.3.2.2.1.
By Component
7.3.2.2.2.
By Workflow
7.3.2.2.3.
By Software Type
7.3.2.2.4.
By Technology
7.3.2.2.5.
By Therapeutic Area
7.3.2.2.6.
By End User
7.3.3. Mexico In Silico
Drug Discovery Market Outlook
7.3.3.1.
Market Size & Forecast
7.3.3.1.1.
By Value
7.3.3.2.
Market Share & Forecast
7.3.3.2.1.
By Component
7.3.3.2.2.
By Workflow
7.3.3.2.3.
By Software Type
7.3.3.2.4.
By Technology
7.3.3.2.5.
By Therapeutic Area
7.3.3.2.6.
By End User
8.
Europe In Silico Drug Discovery Market Outlook
8.1. Market Size &
Forecast
8.1.1. By Value
8.2. Market Share &
Forecast
8.2.1. By Component (Software, Software-as-a-Service,
Consultancy-as-a-Service)
8.2.2. By Workflow (Discovery, Pre-Clinical Tests, Clinical
Trials)
8.2.2.1.
By Discovery (Target
Identification, Target Validation, Lead Discovery)
8.2.3. By Software Type (Molecular Modeling & De Novo Drug Design
Software, Pharmacophore Modeling Software)
8.2.4. By Technology (Artificial Intelligence, Graphics
Processing Unit, Others)
8.2.5. By Therapeutic Area (Human Immunodeficiency Virus (HIV),
Infectious Diseases, Metabolic Disorders, Oncology Disorders, Others)
8.2.6. By End User (Biotechnology & Pharmaceutical
Companies, Contract Research Organizations, Academic & Research
Organizations, Others)
8.2.7. By Country
8.3. Europe: Country
Analysis
8.3.1. France In Silico
Drug Discovery Market Outlook
8.3.1.1.
Market Size & Forecast
8.3.1.1.1.
By Value
8.3.1.2.
Market Share & Forecast
8.3.1.2.1.
By Component
8.3.1.2.2.
By Workflow
8.3.1.2.3.
By Software Type
8.3.1.2.4.
By Technology
8.3.1.2.5.
By Therapeutic Area
8.3.1.2.6.
By End User
8.3.2. Germany In Silico
Drug Discovery Market Outlook
8.3.2.1.
Market Size & Forecast
8.3.2.1.1.
By Value
8.3.2.2.
Market Share & Forecast
8.3.2.2.1.
By Component
8.3.2.2.2.
By Workflow
8.3.2.2.3.
By Software Type
8.3.2.2.4.
By Technology
8.3.2.2.5.
By Therapeutic Area
8.3.2.2.6.
By End User
8.3.3. United Kingdom In
Silico Drug Discovery Market Outlook
8.3.3.1.
Market Size & Forecast
8.3.3.1.1.
By Value
8.3.3.2.
Market Share & Forecast
8.3.3.2.1.
By Component
8.3.3.2.2.
By Workflow
8.3.3.2.3.
By Software Type
8.3.3.2.4.
By Technology
8.3.3.2.5.
By Therapeutic Area
8.3.3.2.6.
By End User
8.3.4. Italy In Silico Drug
Discovery Market Outlook
8.3.4.1.
Market Size & Forecast
8.3.4.1.1.
By Value
8.3.4.2.
Market Share & Forecast
8.3.4.2.1.
By Component
8.3.4.2.2.
By Workflow
8.3.4.2.3.
By Software Type
8.3.4.2.4.
By Technology
8.3.4.2.5.
By Therapeutic Area
8.3.4.2.6.
By End User
8.3.5. Spain In Silico Drug
Discovery Market Outlook
8.3.5.1.
Market Size & Forecast
8.3.5.1.1.
By Value
8.3.5.2.
Market Share & Forecast
8.3.5.2.1.
By Component
8.3.5.2.2.
By Workflow
8.3.5.2.3.
By Software Type
8.3.5.2.4.
By Technology
8.3.5.2.5.
By Therapeutic Area
8.3.5.2.6.
By End User
9.
Asia-Pacific In Silico Drug Discovery Market Outlook
9.1. Market Size &
Forecast
9.1.1. By Value
9.2. Market Share &
Forecast
9.2.1. By Component (Software, Software-as-a-Service,
Consultancy-as-a-Service)
9.2.2. By Workflow (Discovery, Pre-Clinical Tests, Clinical
Trials)
9.2.2.1.
By Discovery (Target
Identification, Target Validation, Lead Discovery)
9.2.3. By Software Type (Molecular Modeling & De Novo Drug Design
Software, Pharmacophore Modeling Software)
9.2.4. By Technology (Artificial Intelligence, Graphics
Processing Unit, Others)
9.2.5. By Therapeutic Area (Human Immunodeficiency Virus (HIV),
Infectious Diseases, Metabolic Disorders, Oncology Disorders, Others)
9.2.6. By End User (Biotechnology & Pharmaceutical
Companies, Contract Research Organizations, Academic & Research
Organizations, Others)
9.2.7. By Country
9.3. Asia-Pacific:
Country Analysis
9.3.1. China In Silico Drug
Discovery Market Outlook
9.3.1.1.
Market Size & Forecast
9.3.1.1.1.
By Value
9.3.1.2.
Market Share & Forecast
9.3.1.2.1.
By Component
9.3.1.2.2.
By Workflow
9.3.1.2.3.
By Software Type
9.3.1.2.4.
By Technology
9.3.1.2.5.
By Therapeutic Area
9.3.1.2.6.
By End User
9.3.2. India In Silico Drug
Discovery Market Outlook
9.3.2.1.
Market Size & Forecast
9.3.2.1.1.
By Value
9.3.2.2.
Market Share & Forecast
9.3.2.2.1.
By Component
9.3.2.2.2.
By Workflow
9.3.2.2.3.
By Software Type
9.3.2.2.4.
By Technology
9.3.2.2.5.
By Therapeutic Area
9.3.2.2.6.
By End User
9.3.3. Japan In Silico Drug
Discovery Market Outlook
9.3.3.1.
Market Size & Forecast
9.3.3.1.1.
By Value
9.3.3.2.
Market Share & Forecast
9.3.3.2.1.
By Component
9.3.3.2.2.
By Workflow
9.3.3.2.3.
By Software Type
9.3.3.2.4.
By Technology
9.3.3.2.5.
By Therapeutic Area
9.3.3.2.6.
By End User
9.3.4. South Korea In
Silico Drug Discovery Market Outlook
9.3.4.1.
Market Size & Forecast
9.3.4.1.1.
By Value
9.3.4.2.
Market Share & Forecast
9.3.4.2.1.
By Component
9.3.4.2.2.
By Workflow
9.3.4.2.3.
By Software Type
9.3.4.2.4.
By Technology
9.3.4.2.5.
By Therapeutic Area
9.3.4.2.6.
By End User
9.3.5. Australia In Silico
Drug Discovery Market Outlook
9.3.5.1.
Market Size & Forecast
9.3.5.1.1.
By Value
9.3.5.2.
Market Share & Forecast
9.3.5.2.1.
By Component
9.3.5.2.2.
By Workflow
9.3.5.2.3.
By Software Type
9.3.5.2.4.
By Technology
9.3.5.2.5.
By Therapeutic Area
9.3.5.2.6.
By End User
10.
South America In Silico Drug Discovery Market Outlook
10.1.
Market Size & Forecast
10.1.1. By Value
10.2.
Market Share & Forecast
10.2.1. By Component (Software, Software-as-a-Service,
Consultancy-as-a-Service)
10.2.2. By Workflow (Discovery, Pre-Clinical Tests, Clinical
Trials)
10.2.2.1. By Discovery (Target Identification, Target Validation,
Lead Discovery)
10.2.3. By Software Type (Molecular Modeling & De Novo Drug
Design Software, Pharmacophore Modeling Software)
10.2.4. By Technology (Artificial Intelligence, Graphics
Processing Unit, Others)
10.2.5. By Therapeutic Area (Human Immunodeficiency Virus (HIV),
Infectious Diseases, Metabolic Disorders, Oncology Disorders, Others)
10.2.6. By End User (Biotechnology & Pharmaceutical
Companies, Contract Research Organizations, Academic & Research
Organizations, Others)
10.2.7. By Country
10.3.
South America: Country Analysis
10.3.1. Brazil In Silico
Drug Discovery Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1.
By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1.
By Component
10.3.1.2.2.
By Workflow
10.3.1.2.3.
By Software Type
10.3.1.2.4.
By Technology
10.3.1.2.5.
By Therapeutic Area
10.3.1.2.6.
By End User
10.3.2. Argentina In Silico
Drug Discovery Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1.
By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1.
By Component
10.3.2.2.2.
By Workflow
10.3.2.2.3.
By Software Type
10.3.2.2.4.
By Technology
10.3.2.2.5.
By Therapeutic Area
10.3.2.2.6.
By End User
10.3.3. Colombia In Silico
Drug Discovery Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1.
By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1.
By Component
10.3.3.2.2.
By Workflow
10.3.3.2.3.
By Software Type
10.3.3.2.4.
By Technology
10.3.3.2.5.
By Therapeutic Area
10.3.3.2.6.
By End User
11.
Middle East and Africa In Silico Drug Discovery Market Outlook
11.1.
Market Size & Forecast
11.1.1. By Value
11.2.
Market Share & Forecast
11.2.1. By Component (Software, Software-as-a-Service,
Consultancy-as-a-Service)
11.2.2. By Workflow (Discovery, Pre-Clinical Tests, Clinical Trials)
11.2.2.1. By Discovery (Target Identification, Target Validation,
Lead Discovery)
11.2.3. By Software Type (Molecular Modeling & De Novo Drug
Design Software, Pharmacophore Modeling Software)
11.2.4. By Technology (Artificial Intelligence, Graphics
Processing Unit, Others)
11.2.5. By Therapeutic Area (Human Immunodeficiency Virus (HIV),
Infectious Diseases, Metabolic Disorders, Oncology Disorders, Others)
11.2.6. By End User (Biotechnology & Pharmaceutical
Companies, Contract Research Organizations, Academic & Research
Organizations, Others)
11.2.7. By Country
11.3.
MEA: Country Analysis
11.3.1. South Africa In
Silico Drug Discovery Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1.
By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1.
By Component
11.3.1.2.2.
By Workflow
11.3.1.2.3.
By Software Type
11.3.1.2.4.
By Technology
11.3.1.2.5.
By Therapeutic Area
11.3.1.2.6.
By End User
11.3.2. Saudi Arabia In
Silico Drug Discovery Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1.
By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1.
By Component
11.3.2.2.2.
By Workflow
11.3.2.2.3.
By Software Type
11.3.2.2.4.
By Technology
11.3.2.2.5.
By Therapeutic Area
11.3.2.2.6.
By End User
11.3.3. UAE In Silico Drug
Discovery Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1.
By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1.
By Component
11.3.3.2.2.
By Workflow
11.3.3.2.3.
By Software Type
11.3.3.2.4.
By Technology
11.3.3.2.5.
By Therapeutic Area
11.3.3.2.6.
By End User
11.3.4. Turkey In Silico
Drug Discovery Market Outlook
11.3.4.1. Market Size & Forecast
11.3.4.1.1.
By Value
11.3.4.2. Market Share & Forecast
11.3.4.2.1.
By Component
11.3.4.2.2.
By Workflow
11.3.4.2.3.
By Software Type
11.3.4.2.4.
By Technology
11.3.4.2.5.
By Therapeutic Area
11.3.4.2.6.
By End User
11.3.5. Egypt In Silico Drug
Discovery Market Outlook
11.3.5.1. Market Size & Forecast
11.3.5.1.1.
By Value
11.3.5.2. Market Share & Forecast
11.3.5.2.1.
By Component
11.3.5.2.2.
By Workflow
11.3.5.2.3.
By Software Type
11.3.5.2.4.
By Technology
11.3.5.2.5.
By Therapeutic Area
11.3.5.2.6.
By End User
12. Market Dynamics
12.1.
Drivers
12.2.
Challenges
13. Market Trends &
Developments
14. Competitive
Landscape
14.1.
Aragen Life Sciences Pvt. Ltd. (GVK Biosciences Pvt. Ltd.)
14.2.
Curia Global, Inc. (Albany Molecular Research Inc.)
14.3.
Charles River Laboratories International, Inc.
14.4.
Chemical Computing Group ULC. (CCG)
14.5.
Collaborative Drug Discovery Inc. (CDD)
14.6.
e-therapeutics plc.
14.7.
Dassault Systèmes SE
14.8.
Insilico Medicine, Inc.
14.9.
Numerate, Inc.
14.10.
Schrödinger, Inc.
15. Strategic Recommendations